

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Medibio Limited
<b>ABN</b>	58 008 130 336

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Peter Carlisle
<b>Date of last notice</b>	20 December 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	10 December 2021
<b>No. of securities held prior to change</b>	125,500 Ordinary Fully Paid Shares; 559,556 Unlisted Options exercisable at \$0.44, expiring 18 June 2022; 4,000,000 Unlisted Options exercisable at \$0.014 expiring 13 June 2023; 3,600,000 Unlisted Options exercisable at \$0.011 (1.1 cents) per option expiring on 20 December 2023.
<b>Class</b>	Fully Paid Ordinary Shares
<b>Number acquired</b>	5,989,625
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Deemed issue prices between \$0.007-\$0.012 per share in lieu of Director Remuneration to a total value of \$56,250.

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	6,115,125 Ordinary Fully Paid Shares; 559,556 Unlisted Options exercisable at \$0.44, expiring 18 June 2022; 4,000,000 Unlisted Options exercisable at \$0.014 expiring 13 June 2023; 3,600,000 Unlisted Options exercisable at \$0.011 (1.1 cents) per option expiring on 20 December 2023.
	Issue of fully paid ordinary shares as approved by shareholders on 11 November 2021 at the Company's Annual General Meeting.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.